s&o logo
  • News
  • Trade Ideas
  • Education
  • Community
Sign Up!
Featured, News, Trade Ideas

MySize Reports Strong Revenue Growth and Expands Global Footprint

December 27, 2024 Elisa Clay No comments yet

MySize, Inc. (NASDAQ: MYSZ), a global leader in AI-powered sizing solutions and omnichannel e-commerce platforms, has released its annual shareholder update, showcasing a year of impressive growth, strategic advancements, and promising future opportunities.

Delivering on Revenue and Efficiency

MySize projects closing 2024 with $8.5 million in revenue, marking a 23% year-over-year increase. The company attributes this robust growth to the expanding footprint of its e-commerce platform, Orgad, and transformative technological advancements. Looking ahead, MySize aims to reach $15 million in revenue by 2025, driven by favorable market conditions and strategic initiatives.

Additionally, the company anticipates significant operational cost savings, enhancing cash flow flexibility and enabling further strategic investments. “Our preliminary financial results highlight Orgad’s pivotal role in driving our revenue growth,” said Ronen Luzon, Founder and CEO of MySize. “2024 has proven that our strategy is not just ambitious but highly effective, laying the groundwork for sustainable growth.”

Expanding into Europe

A cornerstone of MySize’s strategy is the geographic expansion of Orgad. While historically focused on North America, Orgad is now establishing a strong presence in Europe. This move follows a key certification to become a supplier for a major European retailer, signaling new growth opportunities in one of the largest retail markets globally.

“We believe that Europe represents a significant opportunity for Orgad as we tap into new markets and strengthen relationships with global retail leaders,” Luzon noted. “The certification underscores our commitment to delivering excellence and demonstrates our ability to adapt to emerging opportunities.”

M&A and Technological Innovation

As part of its growth strategy, MySize is actively exploring mergers and acquisitions within its core industries. This approach aims to strengthen its market position, enhance technological capabilities, and broaden its service offerings.

With cutting-edge AI-driven sizing solutions and an omnichannel approach, MySize continues to redefine e-commerce experiences. The company’s focus on innovation, strategic market expansion, and financial efficiency positions it for sustained success.

MySize’s achievements in 2024 highlight its ability to execute ambitious strategies and capitalize on global opportunities, setting the stage for a transformative year ahead.

You might like this article: Telomir Pharmaceuticals Advances Copper-Binding Research with Telomir-1

  • Movers
  • My Size
  • MYSZ
  • Stock Market
  • Stocks

Post navigation

Previous
Next

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Education (15)
  • Featured (46)
  • News (85)
  • Trade Ideas (39)

Recent posts

  • FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity
  • Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine
  • flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

Tags

BDRX CDT Conduit Conference Call CURR CURRENC Earnings Evergreen GH Research GHRS Grail GRAL HOLO IINN Inspira Technologies Interview IPWR JTAI KULR LCID Litigation LLY Lucid Motors M&A MedTech MicroCloud Movers MSTR My Size MYSZ News NLSP Novo Nordisk NVO Options Partnerships QNTM Quantum BioPharma Stock Market Stocks TAOP TELO Telomir Pharmaceuticals Traws Pharma TRWS

Continue reading

Featured, News, Trade Ideas

FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity

March 3, 2025 Elisa Clay No comments yet

BioXcel Therapeutics (BTAI) announced that the U.S. Food and Drug Administration (FDA) has officially closed its inspection of a single site involved in the TRANQUILITY II Phase 3 trial under 21 C.F.R.20.64(d)(3). The FDA’s designation of “Voluntary Action Indicated” (VAI) signals that while minor issues may have been identified, no regulatory action is required, further […]

Featured, News, Trade Ideas

Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine

February 20, 2025 Elisa Clay No comments yet

Telomir Pharmaceuticals (NASDAQ: TELO) has achieved a major scientific breakthrough by stabilizing Silver(II) (Ag²⁺) using its proprietary compound, Telomir-1. This advancement overcomes a key challenge in silver-based medicine, unlocking new possibilities for antimicrobial treatments, wound care, and infection-resistant medical coatings. Silver(II) offers superior antibacterial action, faster wound healing, and immune-modulating properties compared to traditional Silver(I) […]

Featured, News, Trade Ideas

flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

February 14, 2025 Elisa Clay No comments yet

flyExclusive (NYSE American: FLYX), a leading provider of premium jet charter experiences, has entered into a definitive agreement to acquire the aviation business of Jet.AI (NASDAQ: JTAI). The deal will allow flyExclusive to expand its fleet and market presence while enabling Jet.AI to transition into a pure-play AI solutions company. Under the terms of the […]

s&o logo

Our primary goal is to empower retail investors with helpful news, guides and trading ideas.

Helpful Links
  • News
  • Trade Ideas
  • Education
  • Community
Resources
  • Privacy Policy
  • Terms & Conditions
  • Contact
Get in touch
  • Email us!

© Copyright 2024, stocks&options. All Rights Reserved.